Xynomic Pharma, Janssen R&D and MSK to initiate Phase I/II trial for lymphoma. Credit: Xynomic Pharmaceuticals Inc.

US-based oncology drug development company Xynomic Pharma is set to begin a Phase I/II trial that will see the combination of Abexinostat with Ibrutinib to treat relapsed/refractory diffuse large b-cell lymphoma (r/r DLBCL) and mantle cell lymphoma (r/r MCL).

Janssen R&D and Memorial Sloan Kettering Cancer Center (MSK) will also partner with Xynomic Pharmato to conduct the trial, which will enrol 40 patients.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

To be led by MSK’s Dr Anita Kumar and Dr Anas Younes, the trial will evaluate the safety and efficacy of the combination of Abexinostat and Ibrutinib in patients with r/r DLBCL or r/r MCL.

The proposed study will also explore the biologic predictors of response and resistance to dual BCRi and HDACi inhibition.

Xynomic Pharma chairman and CEO Mark Xu said: “One of the most important paradigm shifts in today’s cancer treatment landscape is the increasing reliance on combination therapies, as it becomes apparent that no single agent, being a targeted therapy or an I-O therapy, can win the battle against a particular type of tumour alone in the long run.

“Combination therapy is the best approach to block multiple oncogenic pathways to ensure effective and sustainable treatment outcome.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
“Combination therapy is the best approach to block multiple oncogenic pathways to ensure effective and sustainable treatment outcome.”

“Dr Younes’ team has shown convincing evidence of potential synergy between Abexinostat and Ibrutinib.”

Abexinostat is a new HDAC inhibitor and is currently undergoing Phase III trials against non-Hodgkin’s lymphoma and renal cell carcinoma.

Ibrutinib is a BTK inhibitor which is jointly developed and commercialised as Imbruvica by Janssen Biotech and Pharmacyclics.

The drug has already been approved for the treatment of multiple haematological malignancies and chronic graft-versus-host-disease (cGVHD).

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact